Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
- 31 March 1992
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 28 (2-3), 644-648
- https://doi.org/10.1016/s0959-8049(05)80117-0
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- The long term prognostic significance of c-erbB-2 in primary breast cancerBritish Journal of Cancer, 1991
- c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodesBritish Journal of Cancer, 1991
- c-erbB-2 oncoprotein expression in primary and advanced breast cancerBritish Journal of Cancer, 1991
- Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situBreast Cancer Research and Treatment, 1991
- Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situHuman Pathology, 1990
- Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysisThe Journal of Pathology, 1990
- Breast cancer and a proto-oncogene.BMJ, 1989
- Neu-Protein Overexpression in Breast CancerThe New England Journal of Medicine, 1988
- Expression of the c‐erbB‐2 protein in normal and transformed cellsInternational Journal of Cancer, 1987
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987